Related Experiment Video
Updated: Jul 14, 2026

10:50
Assessment of Immunologically Relevant Dynamic Tertiary Structural Features of the HIV-1 V3 Loop Crown R2 Sequence by ab initio Folding
Published on: September 15, 2010
Structural analysis of the HIV-1 gp120 V3 loop: application to the HIV-Haiti isolates
1Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, Kuprevich St. 5/2, 220141 Minsk, Republic of Belarus. andrianov@iboch.bas-net.by
Journal of Biomolecular Structure & Dynamics
|May 19, 2007
Summary
The HIV-Haiti V3 loop
Area of Science:
- Structural biology
- Virology
- Computational chemistry
Background:
- The V3 loop of HIV-1 gp120 is a critical determinant of viral tropism and a key target for neutralizing antibodies.
- Understanding the conformational flexibility of the V3 loop is essential for designing effective therapeutics.
Purpose of the Study:
- To model and analyze the structure and conformational preferences of the HIV-Haiti V3 loop.
- To identify conserved structural motifs and key amino acid residues for drug design.
Main Methods:
- NMR spectroscopy data analysis.
- Computer-based 3D structure modeling.
- Conformational analysis of irregular segments.
- Comparison of structures in different solvent environments (water vs. water/TFE).
Main Results:
- The HIV-Haiti V3 loop exhibits significant conformational variability in response to environmental changes, altering secondary and tertiary structures.
- Over half of the amino acid residues in functionally important regions maintain their conformation.
- Key residues like Asn-25 (CD4 binding) and Arg-3 (CCR5 utilization) are conformationally stable.
- A conserved structural motif, including an N-linked glycosylation site, was identified.
Conclusions:
- The HIV-Haiti V3 loop's conformational plasticity is a key feature of this variable gp120 fragment.
- Despite variability, conserved residues and motifs offer potential targets for HIV-1 drug design.
- The identified conserved motif is a promising target for developing new AIDS therapeutics.

